Contemplating hemophilia as a disorder of defective thrombin generation, rather than merely as a deficiency in FVIII or FIX, has traditionally been reserved for patients with inhibitors who require bypassing agents (eg, recombinant VIIa, activated prothrombin complex concentrate), which act by restoring thrombin generation. This evidence concerns the gene F8 and hemophilia.